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Calcium/calmodulin-dependent protein kinase II (CaMKII) is a pivotal signaling molecule in both 
the brain and the heart. In this issue of Cell, Erickson et al. (2008) demonstrate a mechanism for 
CaMKII activation by reactive oxygen species that provides a direct link between kinase activation 
and cardiac dysfunction.The regulation of calcium/calmodulin-
dependent protein kinase II (CaMKII) is 
of intense interest to neuroscientists due 
to its role in neuronal plasticity. However, 
CaMKII also has important functions in 
other tissues such as the heart. In this 
issue of Cell, Erickson et al. (2008) add 
a new piece to the puzzle of CaMKII 
regulation with their demonstration that 
reactive oxygen species (ROS) involve 
activation of CaMKII and cardiac pathol-
ogy. These findings may have important 
implications for our understanding of 
disease mechanisms in both the heart 
and nervous system.
In the brain, the coupling of cell exci-
tation and Ca2+ influx to the calmodulin- 
(Ca2+/CaM) triggered activation of CaM-
KII is a critical signaling mechanism. 
The cardinal feature of CaMKII, which 
is believed to underlie its role in neu-
ronal plasticity, is its ability to remain 
active independent of Ca2+/CaM bind-
ing after its initial activation (for review, 
see Griffith, 2004). During CaMKII acti-
vation, binding of Ca2+/CaM to the regu-latory domain of CaMKII disrupts the 
interaction between the autoinhibitory 
sequences and the N-terminal catalytic 
domain to allow for substrate phospho-
rylation. Activation also catalyzes auto-
phosphorylation within the autoinhibi-
tory domain at threonine 287 (T287 for 
β, γ, δ isozymes; T286 for αCaMKII). It 
is this threonine phosphorylation that 
gives CaMKII its ability to remain active 
even after dissociation of Ca2+/CaM, 
as the modification prevents the reas-
sociation of the CaMKII autoinhibitory 
domain even in the absence of Ca2+/
CaM. This property of the kinase allows 
it to remain active for a prolonged 
period of time after the Ca2+ concentra-
tion in the cytoplasm has returned to 
basal levels, thereby allowing neurons 
to retain a “memory” of the excitation. 
The CaM-binding domain of the kinase 
can also undergo autophosphorylation 
at T306 and T307. Phosphorylation at 
these sites blocks binding of CaM and 
provides a mechanism for inhibiting 
kinase activation (Lu et al., 2003).CeNeurons are of course not the only 
excitable cells in the body—heart cells 
are also excitable. In the heart, CaM-
KII is known to be critically involved in 
coupling excitation and contraction of 
muscle through regulation of voltage-
gated Na+, K+, and Ca2+ channels as 
well as a variety of Ca2+ handling pro-
teins (Maier and Bers, 2007). Consti-
tutively active CaMKII is elevated in a 
number of pathological conditions of 
the heart and has a pivotal role in medi-
ating cardiac remodeling induced by 
hyperactivation of β-adrenergic recep-
tors (Zhang et al., 2005). Intriguingly, 
CaMKII is also activated by the pro-ox-
idant cellular environment produced in 
many other forms of cardiac dysfunc-
tion. Shear stress, volume overload, 
and reperfusion after anoxia all induce 
the production of ROS through activa-
tion of NADPH oxidase. In addition, a 
diverse collection of agents, including 
angiotensin II, induce translocation 
of the NADPH oxidase subunit p47 to 
the cell membrane. This change in p47 ll 133, May 2, 2008 ©2008 Elsevier Inc. 397
localization results in the production of 
ROS and the activation of kinases and 
transcriptional responses that can lead 
to apoptosis or cardiac hypertrophy.
Erickson and colleagues set out to 
determine how ROS activate CaMKII 
by first examining the effects of a pow-
erful ROS, hydrogen peroxide (H2O2), 
on purified δCaMKII. They found that 
in the presence of Ca2+/CaM, H2O2 
treatment caused CaMKII to become 
constitutively active. Importantly, this 
activation was entirely independent of 
phosphorylation at T287, given that it 
occurred even when the threonine was 
mutated to alanine (T287A). Reasoning 
that this activation had to involve the 
well-characterized regulatory domain 
of CaMKII, the authors used protein 
chemistry to look for oxidative modi-
fications of cysteine and methionine 
residues. They found that oxidation of 
either methionine 281 or methionine 
282 (M281 or M282) could activate the 
kinase, whereas oxidation of cysteines 
or other methionines in this domain had 
no effect. These findings suggest that 
binding of Ca2+/CaM induces a con-
formational change that opens up the 
regulatory domain of the kinase and 
makes these methionines available for 
modification. The requirement for initial 
Ca2+/CaM binding is also a feature of 
T287 phosphorylation, suggesting that 
the regulatory domain is normally pro-
tected by intramolecular interactions in 
the inactive state (Figure 1).
Having identified a new mode of 
residue modification in the regulatory 
domain, the authors then set out to 
explore the physiological role of methi-
onine oxidation in CaMKII. Erickson et 
al. compared the effects of two agents 
that are known to be involved in car-
diac tissue remodeling: the hormone 
angiotensin II, which increases the gen-
eration of ROS, and the β-adrenergic 
agonist isoproterenol, which increases 
intracellular Ca2+ and activates CaMKII. 
Using an oxidation-specific antibody, 
they showed that oxidation of M281/282 
occurs in vivo in the hearts of angio-
tensin II-treated mice but not in the 
hearts of mice treated with isoprotere-
nol. This suggested that the modifica-
tion is dependent on the presence of 
ROS. Consistent with this, CaMKII oxi-
dation was blocked by mutation of p47, 
the NADPH oxidase subunit responsible 
for increased ROS following angiotensin 
II treatment. Finally, mutation of MsrA, 
the enzyme that regenerates methionine 
from its oxidized form, enhanced oxi-
dation of CaMKII. Though both angio-
tensin II and isoproterenol stimulate 
phosphorylation of δCaMKII at T287, 
angiotensin II-stimulated phosphoryla-
tion was blocked by mutation of p47. 
This suggested that ROS also have 
effects, possibly mediated by regula-
tion of phosphatases, on the steady-
state levels of phosphorylated T287. 
Both oxidation and phosphorylation of 
the regulatory domain were blocked in 
mice expressing AC3I, a peptide inhibi-
tor of CaMKII, supporting the role of ini-
tial kinase activation in the generation 
of these distinct constitutively active 
species.
The authors go on to establish the 
clinical relevance of CaMKII activa-
tion by oxidation in a very elegant set 
of experiments. In cultured cardiac 
myocytes, they showed that follow-
ing downregulation of endogenous 
δCaMKII with a short hairpin RNA 
(shRNA), expression of shRNA-resis-
tant wild-type δCaMKII supported both 
angiotensin II- and isoproterenol-stim-
ulated apoptosis. In contrast, expres-
sion of a mutant kinase in which M281 
and M282 are replaced by valines 
(M281/282V) only supported β-agonist 
isoproterenol-triggered cell death. The 
authors coupled these exciting results 
with additional experiments showing 
that mice with surgically induced myo-
cardial infarction had increased CaM-
KII M281/282 oxidation and that MsrA 
mutant mice have worse outcomes in 
terms of cardiac function and mortality. 
These findings together build a strong 
case for oxidative modification of CaM-
KII as a significant contributor to ROS-
mediated pathology.
This study, together with previous work 
from this group (Zhang et al., 2005), places 
CaMKII activation at the heart of the path-
ological mechanisms of both β-adrenergic 
and ROS-mediated cardiac damage. Both 
pathways are activated in the context of 
elevated Ca2+ levels in the beating heart 
and can cause autophosphorylation-de-
pendent activation of CaMKII. This study 
demonstrates that signaling molecules that 
generate ROS have an additional mecha-
nism for the activation of CaMKII via oxida-
tion. Given that the localization of CaMKII is 
critical to its specificity (Schulman, 2004), it 
will be interesting to see if oxidation-mod-
ified CaMKII and phosphorylated CaMKII 
are differentially localized within the myo-
cyte or whether they act on different sets 
of effectors. In both cases, inhibiting CaM-
figure 1. Modifying the δcaMKII Regulatory Domain
The CaMKII regulatory domain is defined as amino acids 282–311 (numbering for δCaMKII; see Hudmon 
and Schulman, 2002 for review), with an overlapping autoinhibitory domain (green) and a CaM-binding 
domain (blue). Binding of Ca2+/CaM activates CaMKII by disrupting interactions between the autoinhibi-
tory domain and the catalytic substrate-binding site and ATP-binding site. Activation of CaMKII results in 
autophosphorylation of threonine 287 (T287), which keeps the enzyme active even if Ca2+/CaM dissociates. 
Phosphorylation within the CaM-binding domain at T306 or T307 can occur when CaM dissociates from 
CaMKII phosphorylated on T287 (Patton et al., 1990) or when unphosphorylated CaMKII is in a complex 
with CASK (at low Ca2+ concentrations), a MAGUK scaffolding protein (Lu et al., 2003). This phosphoryla-
tion blocks subsequent Ca2+/CaM binding and activation of CaMKII. Erickson et al. (2008) show that M281/
M282 can also be modified by oxidation to generate Ca2+/CaM-independent activity, suggesting that our 
definition of the regulatory domain of CaMKII should be expanded to include these residues.398 Cell 133, May 2, 2008 ©2008 Elsevier Inc.
KII in the heart may be an appealing thera-
peutic approach for preventing sudden 
death following a heart attack. Moreover, 
ROS-dependent pathology is important 
in many neurological conditions including 
Alzheimer’s disease (Infanger et al., 2006) 
and the vascular dysfunction that follows 
subarachnoid hemorrhage (Zemke et al., 
2007). The ability of CaMKII to be directly 
stimulated by the generation of ROS may 
connect this versatile enzyme to a variety 
of other diseases.The serine/threonine protein kinase Akt 
is activated by a wide range of stimuli, 
such as growth factors and cytokines 
(Manning and Cantley, 2007), and has 
been implicated in many aspects of 
cellular regulation, including cell sur-
vival, growth, proliferation, migration, 
and metabolism. Likewise, numerous 
Akt substrates have been identified that 
mediate these effects (Figure 1). Because 
phosphorylation of specific Akt sub-
strates determines the cellular response, 
a major question in Akt signaling is how 
substrate selectivity is achieved. In this 
issue, Schenck et al. (2008) provide evi-
dence for the role of spatial regulation in 
Akt signaling. They show that the binding 
of Akt to the endosomal protein Appl1 
contributes to Akt’s substrate selectivity 
and promotes cell survival in zebrafish 
development.
Human APPL1 (adaptor protein con-
taining PH domain, PTB domain, and 
leucine zipper) was originally identified 
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as an Akt-interacting protein (Mitsuuchi 
et al., 1999). Subsequent studies have 
established that APPL1 is a direct down-
stream effector of Rab5 (Miaczynska et 
al., 2004), a GTPase involved in endo-
cytosis. In new work using a zebrafish 
model, Schenck et al. now show that 
downregulation of Appl1 or Appl2 by anti-
sense morpholinos markedly increases 
apoptosis in tissues that normally have 
high levels of expression of Appl1 and 
Appl2 (Schenck et al., 2008). A role for 
Appl2 in cell survival during development 
is further supported by genetic mutation 
analyses.
Previous work has shown that activ-
ity of mammalian Akt is enhanced by 
binding to APPL1 in response to various 
signals. Similarly, Schenck et al. show 
that activation of Akt by growth factor 
stimulation is diminished by morpholino 
knockdown of Appl1 in zebrafish. Based 
on these and other findings the authors 
conclude that Appl1 is essential for the 
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prosurvival function of Akt. They then 
examined the effect of depleting Appl1 
on the phosphorylation of two Akt sub-
strates, glycogen synthase kinase 3 
(Gsk3) and tuberous sclerosis protein 2 
(Tsc2). Surprisingly, inactivation of Appl1 
only decreases the phosphorylation of 
Gsk3 but not Tsc2 (Figure 1), suggest-
ing that Appl1 may affect the substrate 
selectivity of Akt in vivo.
The colocalization of APPL1 with Akt 
and GSK3, but not TSC2, further sup-
ports the notion that Appl1 regulates 
Akt substrate selectivity (Schenck et al., 
2008). Human APPL1 is localized in mul-
tiple cellular compartments, including 
endosomes (Miaczynska et al., 2004). 
Schenck et al. show that stimulation of 
HeLa cells by insulin-like growth factor 
1 (IGF-1) results in a transient colocal-
ization of Akt and APPL1 in endosomes. 
Importantly, a fraction of APPL1-pos-
itive endosomes also display positive 
staining for GSK3, and IGF-1 treatment 
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